Commonwealth of Pennsylvania Public School Empls Retrmt SYS Boosts Stake in Hologic, Inc. $HOLX

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 6.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 54,654 shares of the medical equipment provider’s stock after buying an additional 3,339 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Hologic were worth $3,561,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Capital Investment Counsel Inc lifted its position in shares of Hologic by 2.6% during the second quarter. Capital Investment Counsel Inc now owns 5,814 shares of the medical equipment provider’s stock worth $379,000 after purchasing an additional 150 shares during the last quarter. Greenleaf Trust grew its holdings in shares of Hologic by 5.1% in the second quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider’s stock worth $233,000 after purchasing an additional 173 shares during the last quarter. Savant Capital LLC increased its stake in Hologic by 1.2% in the 2nd quarter. Savant Capital LLC now owns 19,606 shares of the medical equipment provider’s stock worth $1,278,000 after buying an additional 232 shares during the period. First American Bank lifted its holdings in Hologic by 0.9% during the 2nd quarter. First American Bank now owns 28,705 shares of the medical equipment provider’s stock valued at $1,870,000 after buying an additional 245 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its position in Hologic by 1.7% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 14,788 shares of the medical equipment provider’s stock valued at $964,000 after buying an additional 246 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 0.1%

Shares of NASDAQ:HOLX opened at $74.17 on Thursday. The company has a market capitalization of $16.50 billion, a PE ratio of 30.78, a P/E/G ratio of 2.54 and a beta of 0.65. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $80.31. The business’s fifty day simple moving average is $70.24 and its 200-day simple moving average is $66.10.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.03 billion. During the same period in the prior year, the business posted $1.01 EPS. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. As a group, equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. BTIG Research reaffirmed a “neutral” rating on shares of Hologic in a research note on Tuesday, October 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a research report on Friday, October 31st. Raymond James Financial cut Hologic from a “moderate buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Leerink Partners raised their price target on Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a research note on Tuesday, October 21st. Finally, Royal Bank Of Canada upgraded Hologic from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $72.00 to $87.00 in a report on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $79.77.

Insider Transactions at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction on Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the transaction, the director directly owned 47,336 shares in the company, valued at $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.88% of the stock is currently owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.